title: Intrapericardial and intrapleural administration of rituximab to a patient with marginal zone lymphoma.
abstract: The addition of rituximab to standard chemotherapy has improved the results of the treatment of B cell non-Hodgkin's lymphomas. Under specific circumstances, it can be administered locally, as an alternative to systemic administration. We administered rituximab intrapericardially in an attempt to control pericardial effusion. We report the case of an 85-year-old woman, diagnosed with marginal zone lymphoma, who developed heart failure due to lymphomatous infiltration of the pericardium. We discuss in detail the possibility of intrapericardial treatment of such patients. The patient received rituximab intrapericardially at a dose of 100 mg in addition to systemic rituximab, cyclophosphamide, vincristine and prednisone immunochemotherapy. The treatment proved to be safe and effective. The patient has remained in good health for more than 3 years at the time of writing. Intrapericardial administration of rituximab may be a valuable therapeutic option for patients with lymphoma that involves the pericardium and heart.
authors.affiliation: Department of Haematology, Oncology and Internal Medicine, The Medical University of Warsaw, Warsaw, Poland.
authors.forename: Piotr
authors.initials: P
authors.lastname: Boguradzki
authors.forename: Joanna Ewa
authors.initials: JE
authors.lastname: Drozd-Sokolowska
authors.forename: Jolanta
authors.initials: J
authors.lastname: Wieczorek
authors.forename: Robert
authors.initials: R
authors.lastname: Kowalik
authors.forename: Marta
authors.initials: M
authors.lastname: Starczewska
authors.forename: Maria
authors.initials: M
authors.lastname: Krol
authors.forename: Malgorzata
authors.initials: M
authors.lastname: Kobylecka
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Opolski
authors.forename: Wiesław
authors.initials: W
authors.lastname: Wiktor-Jedrzejczak
mesh_terms: D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006338:Heart Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy* / Q000473:pathology; D009361:Neoplasm Invasiveness; D010490:Pericardial Effusion / Q000188:drug therapy* / Q000473:pathology; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D000069283:Rituximab; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone